ImmunityBio stock
Price history
+197.29% over the period1 year: from $2.03 (November 17, 2025) to $6.04 (November 16, 2026), +197.29%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $6.04 |
| October 30, 2026 | $8.29 |
| September 30, 2026 | $9.44 |
| August 31, 2026 | $7.95 |
| July 31, 2026 | $7.17 |
| June 30, 2026 | $8.76 |
| May 29, 2026 | $7.52 |
| April 30, 2026 | $7.10 |
| March 31, 2026 | $7.67 |
| February 27, 2026 | $9.78 |
| January 30, 2026 | $6.25 |
| December 31, 2025 | $1.98 |
| November 28, 2025 | $2.36 |
| November 17, 2025 | $2.03 |
At a glance
The company
Biotechnology company developing next-generation immunotherapies to activate the immune system against cancer and infectious diseases
Latest results
Quarter to September 30, 2026 · EPS -$0.09 (estimate -$0.08)
TickerLandia's take on ImmunityBio
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−51.45% from the 52-week high
Analysts · 4 analysts
Average target$14.25+136.12% vs. price
Buy 4 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: ImmunityBio
Compared with similar companies: very low earnings stability, very high growth, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Profitabilityaverage47
How much it earns on revenue and capital.
Metric Value Position in group ROE 122.9% 94 ROA −30.4% 9 Gross margin 98.8% 91 Operating marginabove 100%: likely one-off items −150.2% 11 Net margin 0.0% 30 Earnings stabilityvery low6
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 59,809.0% 1 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthvery high88
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +678.62% 99 Revenue growth (year over year) +52.30% 80 Earnings growth (year over year) +110.54% 85 Financial strengthhigh64
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −2.28 27 Debt/equitycounts in reverse: lower means more financial strength · negative shareholders' equity −1.17 98 Current ratio 4.27 66 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak33
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +201.00% 99 Distance from 200-day average −24.47% 7 Relative strength (3 months) −18.84% 12 Relative strength (6 months) −27.28% 11 Riskvery high86
How much the price swings.
Metric Value Position in group Volatility (60 days) 86.6% 96 Beta (1 year) 1.52 78 Maximum drawdown (12 months) 47.9% 83
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
How ImmunityBio is valued
Compared with 11 similar companies
| Metric | ImmunityBio | Position in the group | Band |
|---|---|---|---|
| Operating margin | -150.2% | Low | |
| ROE | 122.9% | High | |
| Debt/equity | -1.17 | Low | |
| Net margin | 0.0% | Middle | |
| Price/sales | 35.1 | High |
Grey band: the middle half of the group; tick: the median; dot: ImmunityBio. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$51.24M
Latest quarter · Q2 2026
Net income
-$230.38M
Latest quarter · Q2 2026
Quarterly net margin
-449.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $6.4B
- EPS
- -$1.06
- Volume
- 13.3M
- Daily trading
- €92.87M
- Dividend yield
- 0.00%
How ImmunityBio is changing
All resultsRevenue grew 184.8% a year on average over the last 5 years
Operating margin rose from −146,374.2% to −226.0%
Shares outstanding up 144.0% in 5 years
Returns
ImmunityBio returns
$1,000 invested in ImmunityBio 5 years ago, on November 16, 2021, would be worth $854 today: −14.64% in total, −3.12% per year. This is the price return only: dividends are excluded.
| Period | ImmunityBio | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −34.26% | −3.12% | $657 |
| 6 months | −24.28% | +2.07% | $757 |
| Year to date | +204.80% | +10.46% | $3,048 |
| 1 year | +197.29% | +13.33% | $2,973 |
| 3 years | +47.56% | +67.73% | $1,476 |
| 5 years | −14.64% | +60.86% | $854 |
| 10 years | −21.52% | +247.35% | $785 |
Over the last 6 months it has done better than 6% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
ImmunityBio: technical analysis
ImmunityBio shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 85.7% below its all-time closing high ($42.25, February 22, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 33
- Between 30 and 70
- vs 200-session average
- −24.27%
Support and resistance
Price areas where ImmunityBio has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$8.48+40.44%7 touches, last on September 28, 2026
- Resistance$7.72+27.92%3 touches, last on October 26, 2026
- Resistance$6.68+10.69%5 touches, last on July 28, 2026
- Last price$6.04
- Support$5.56−7.87%2 touches, last on February 5, 2026
- Support$2.48−58.91%2 touches, last on December 12, 2025
- Support$1.98−67.27%2 touches, last on December 31, 2025
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.52
- Volatility (60 sessions, annualised)
- 86.6%
- Largest fall in the last year
- −47.88%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ImmunityBio: seasonality
Average monthly price change over 12 years
Over the last 12 years, the strongest month for ImmunityBio has been January: +21.92% on average, positive in 4 years out of 11. The weakest has been March: −9.59% on average, positive in 3 years out of 11. November, the current month, has been positive in 7 years out of 11 (+12.19% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +21.92% | −4.28% | 4 of 11 |
| February | +7.57% | +0.45% | 6 of 11 |
| March | −9.59% | −17.98% | 3 of 11 |
| April | +1.29% | −7.43% | 5 of 11 |
| May | +5.45% | −1.13% | 5 of 11 |
| June | +13.53% | −0.97% | 4 of 11 |
| July | −4.30% | −8.96% | 4 of 11 |
| August | −9.19% | −4.22% | 4 of 12 |
| September | −1.51% | −4.42% | 5 of 12 |
| October | +1.72% | −7.31% | 5 of 12 |
| November | +12.19% | +6.06% | 7 of 11 |
| December | +4.90% | −8.37% | 4 of 11 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ImmunityBio and its competitors
Headquartered in San Diego, California, and in existence since 2014, ImmunityBio develops immunotherapies meant to strengthen the body's own immune response against cancer and infectious diseases. Its development platforms cover fusion proteins built on cytokines, DNA-based and viral vector vaccines, and cell therapies, and its clinical programs address both liquid and solid tumors. Its lead product, Anktiva, holds FDA approval and is used alongside BCG in adults with bladder cancer that no longer responds to BCG, a non-muscle invasive form that includes carcinoma in situ.
- Headquarters
- San Diego, United States
- Employees
- 684
- Founded
- 2014
- Chief executive
- Richard Adcock
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ImmunityBioIBRX | $6.4B | -150.2% | — | −24.28% |
| Twist BioscienceTWST | $7.4B | -28.8% | — | +113.09% |
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +22.80% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −18.72% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.23% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −28.81% |
Same industry or related industries, similar size. Compare ImmunityBio with its competitors · Full profile
